Publications
Gilbert D, Langley R, Ayadi D, Berhanu M, Hemanth L, Kwon S et al. (2026). Drug re-purposing to improve outcomes in the management of prostate cancer - aims, outcome measures and design of current phase III trials. BMC pharmacology & toxicology, 27 (1): 35
https://doi.org/10.1186/s40360-025-01077-w
https://europepmc.org/article/MED/41580831
Gilbert D, Nankivell M, Sehjal J, Rush H, Mangar S, et al. (2025). A0474 – Androgen suppression, PSA response, toxicity and longer-term outcomes with transdermal oestradiol (tE2) patches compared with LHRH analogues for the treatment of locally advanced prostate cancer, the phase III PATCH (NCT00303784) and STAMPEDE (NCT00268476) trials. European Urology, Volume 87, Supplement 2
https://doi.org/10.1016/j.eururo.2025.09.3665
James N, Rush H, Nankivell M, Sehjal J, Mangar S, et al., (2025). Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. Journal of Clinical Oncology, Volume 43, 21 (2025)
DOI: 10.1200/JCO.2025.43.5_suppl.21
Gilbert D, Nankivell M, Rush H, Clarke N, Mangar S, et al. (2024). A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design. Clinical oncology (Royal College of Radiologists (Great Britain)), 36 (1), e11-19
https://doi.org/10.1016/j.clon.2023.10.054
https://europepmc.org/article/MED/37973477
Macnair A, Nankivell M, Murray M, Rosen S, Appleyard S, et al. (2023). Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data. Contemporary clinical trials, 128:107162
https://doi.org/10.1016/j.cct.2023.107162
https://europepmc.org/article/MED/36933612
Langley, R., Gilbert, D., Duong, T., Clarke, N., Nankivell, M., & Rosen, S. et al. (2021). Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. The Lancet, 397(10274), 581-591. https://doi.org/10.1016/s0140-6736(21)00100-8
https://authors.elsevier.com/a/1cZgXV-4XDOCm
Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, Pollock P,
Kockelbergh R, Lalani el-N, Dearnaley D, Parmar M & Abel PD (2008) Early hormonal data
from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal
therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 2008; 102
(4): 442-445.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564109/
Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P Jinks
RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MKB, Abel PD.
Cardiovascular Outcomes in Patients with Locally Advanced and Metastatic Prostate Cancer
Treated with LHRH Agonists or Transdermal Oestrogen in the Randomised Phase II MRC
PATCH Trial (PR09). Lancet Oncology 2013; 14(4): 306-316.
https://www.sciencedirect.com/science/article/pii/S1470204513700251?via%3Dihub
Phillips I, Shah SI, Duong T, Abel P, Langley RE. Androgen Deprivation Therapy and the
Re-emergence of Parenteral Estrogen in Prostate Cancer. Oncol Hematol Rev. 2014 Spring;
10(1):42-47.
https://www.ncbi.nlm.nih.gov/pubmed/24932461
Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, Scrase CD, Robertson
A, Cafferty F, Welland A, Carpenter R, Honeyfield L, Abel RL, Stone M, Parmar MKB, Abel
PD. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced
Prostate Cancer: Luteinising Hormone releasing Hormone Agonists Versus Transdermal
Oestradiol. European Urology 69 (2016) 1016 – 1025.
https://www.ncbi.nlm.nih.gov/pubmed/26707868
Gilbert DC, Duong T, Kynaston HG, Alhasso AA, Cafferty FH, Rosen SD, Kanaga-Sundaram
S, Dixit S, Laniado M, Madaan S, Collins G, Pope A, Welland A, Nankivell M, Wassersug R,
Parmar MKB, Langley RE, Abel PD. Quality-of-life outcomes from the Prostate
Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormonereleasing
hormone agonists versus transdermal oestradiol for androgen suppression in
advanced prostate cancer. BJU Int. 2017 May; 119(5):667-675.
https://www.ncbi.nlm.nih.gov/pubmed/27753182
Posters (available on request)
Langley RE, Kynaston H, Clarke NW, Godsland IF, Rosen SD, Morgan RC, Pollock P, Parmar
MK & Abel PD. PATCH, a randomised phase II trial of oestrogen patches versus LHRH as
first-line hormonal therapy for prostate cancer: Planned interim analysis results.
ASCO Genitourinary Cancers Symposium 2009 Abstract #173.
Abel PD, Sundaram SK, Kynaston HG, Clarke N, Alhasso AA, Rosen SD, Jinks RC, Pollock P,
Cafferty FH and Langley RE. Cardiovascular events and clinical responses in prostate cancer
patients treated with transcutaneous oestrogen patches compared with LHRH analogues:
Results from a randomized phase II trial (MRC PR09 PATCH). J Clin Oncol 2011; 29 (suppl
7; abstract 201).
https://www.ncbi.nlm.nih.gov/pubmed/27968634
Langley RE, Jinks RC, Sundaram SK, Clarke NC, Kynaston HG, Alhasso AA, Rosen SD,
Kockelbergh R, Parmar MK, Pollock P, Cafferty FH and Abel PD. Hormone responses in
prostate cancer patients treated with transcutaneous oestrogen patches: Results from a
randomised phase II Trial (MRC PR09 PATCH). EAU Annual Congress 2011 Abstract #1097.
Langley RE, Duong T, Jovic G, Alhasso AA, Kynaston H, Dearnaley DP, Rosen SD,
Kockelbergh R, Clarke NW, Godsland IF, Sundaram SK, Dixit S, Laniado M, Stockdale A,
Pope A, Paez EM, Spittle B, Bara A, Parmar MKB, Abel PD. PATCH: A randomised controlled
trial of transdermal oestrogen patches versus luteinising hormone-releasing hormone
agonists in locally advanced and metastatic prostate cancer. J Clin Oncol 2014; 32 (suppl
5; abstr TPS5099).
Langley RE, Duong T, Govic F, Cafferty F, Honeyfield L, Abel RL, Stone M, Kynaston H,
Alhasso AA, Scrase CD, Paez EM, Spittle B, Bara A, Parmar MKB, Abel PD. Bone density in
men receiving androgen deprivation therapy for prostate cancer: A randomised comparison
between transdermal oestrogen and luteinising hormone-releasing hormone agonists.
J Clin Oncol 2014; 32 (suppl 5; abstr 5067).
